Patents by Inventor Ilya Chumakov

Ilya Chumakov has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of identifying individuals for inclusion in drug studies
    Patent number: 7105353
    Abstract: The present invention relates to genomic maps comprising biallelic markers, new biallelic markers, and methods of using biallelic markers.
    Type: Grant
    Filed: February 14, 2003
    Date of Patent: September 12, 2006
    Assignee: Serono Genetics Institute S.A.
    Inventors: Daniel Cohen, Marta Blumenfeld, Ilya Chumakov
  • Biallelic markers for use in constructing a high density disequilibrium map of the human genome
    Publication number: 20060177863
    Abstract: The present invention relates to genomic maps comprising biallelic markers, new biallelic markers, and methods of using biallelic markers. Primers hybridizing to regions flanking these biallelic markers are also provided. This invention provides polynucleotides and methods suitable for genotyping a nucleic acid containing sample for one or more biallelic markers of the invention. Further, the invention provides a number of methods utilizing the biallelic markers of the invention including methods to detect a statistical correlation between a biallelic marker allele and a phenotype and/or between a biallelic marker haplotype and a phenotype.
    Type: Application
    Filed: March 8, 2006
    Publication date: August 10, 2006
    Applicant: Serono Genetics Institute S. A.
    Inventors: Daniel Cohen, Ilya Chumakov, Marta Blumenfeld
  • Schizophrenia associated genes, proteins and biallelic markers
    Patent number: 7067627
    Abstract: The invention concerns the human sbg1, g34665, sbg2, g35017 and g35018 genes, polynucleotides, polypeptides biallelic markers, and human chromosome 13q31-q33 biallelic markers. The invention also concerns the association established between schizophrenia and bipolar disorder and the biallelic markers and the sbg1, g34665, sbg2, g35017 and g35018 genes and nucleotide sequences. The invention provides means to identify compounds useful in the treatment of schizophrenia, bipolar disorder and related diseases, means to determine the predisposition of individuals to said disease as well as means for the disease diagnosis and prognosis.
    Type: Grant
    Filed: May 16, 2002
    Date of Patent: June 27, 2006
    Assignee: Serono Genetics Institute S.A.
    Inventors: Daniel Cohen, Marta Blumenfeld, Ilya Chumakov, Lydie Bougueleret, Bernard Bihain, Laurent Essioux
  • Novel kcnq polypeptides, modulators thereof, and their uses in the treatment of mental disorders
    Publication number: 20060099210
    Abstract: The invention encompasses polypeptides and polynucleotides of three novel bipolar disorder-associated potassium channel polypeptides, KCNQ2-15bx, KCNQ2-15by and KCNQ2-15bz. The invention further relates to the use of potassium channels comprising KCNQ2 subunits for screening for modulators thereof, the use of these modulators for treating mental disorders such as bipolar disorder, schizophrenia and depression, and drugs comprising these modulators. The invention also discloses biallelic markers located in the KCNQ2 gene and their use for diagnosing mental disorders.
    Type: Application
    Filed: June 20, 2003
    Publication date: May 11, 2006
    Applicant: Serono Genetics Institute S. A.
    Inventors: Laurent Cavarec, Ilya Chumakov, Benoit Destenaves, Catherine Gonthier, Isabelle Elias
  • Genomic sequence of the purH gene and purH-related biallelic markers
    Patent number: 7041454
    Abstract: The invention concerns the genomic sequence of the purH gene. The invention also concerns biallelic markers of a purH gene and the association established between these markers and cancer, particularly prostate cancer. The invention provides means to determine the predisposition of individuals to cancer as well as means for the diagnosis of cancer and for the prognosis/detection of an eventual treatment response to agents acting on cancer.
    Type: Grant
    Filed: February 27, 2003
    Date of Patent: May 9, 2006
    Assignee: Serono Genetics Institute, S.A.
    Inventors: Marta Blumenfeld, Ilya Chumakov, Lydie Bougueleret, Annick Cohen-Akenine
  • Nucleic acids encoding human TBC-1 protein and polymorphic markers thereof
    Publication number: 20060084073
    Abstract: The invention concerns genomic and cDNA sequences of the human TBC-1 gene. The invention also concerns polypeptides encoded by the TBC-1 gene. The invention also deals with antibodies directed specifically against such polypeptides that are useful as diagnostic reagents. The invention further encompasses biallelic markers of the TBC-1 gene useful in genetic analysis.
    Type: Application
    Filed: October 20, 2004
    Publication date: April 20, 2006
    Applicant: Genset S.A.
    Inventors: Marta Blumenfeld, Lydie Bougueleret, Ilya Chumakov
  • Genomic sequence of the purH gene and purH-related biallelic markers
    Publication number: 20060073512
    Abstract: The invention concerns the genomic sequence of the purH gene. The invention also concerns biallelic markers of a purH gene and the association established between these markers and cancer, particularly prostate cancer. The invention provides means to determine the predisposition of individuals to cancer as well as means for the diagnosis of cancer and for the prognosis/detection of an eventual treatment response to agents acting on cancer.
    Type: Application
    Filed: November 22, 2005
    Publication date: April 6, 2006
    Applicant: Serono Genetics Institute S.A.
    Inventors: Marta Blumenfeld, Ilya Chumakov, Lydie Bougueleret, Annick Cohen-Akenine
  • Biallelic markers related to genes involved in drug metabolism
    Publication number: 20060040304
    Abstract: The invention provides polynucleotides including biallelic markers derived from genes involved in the biotransformation of xenobiotics such as drugs and from genomic regions flanking those genes. Primers hybridizing to regions flanking these biallelic markers are also provided. This invention also provides polynucleotides and methods suitable for genotyping a nucleic acid containing sample for one or more biallelic markers of the invention. Further, the invention provides methods to detect a statistical correlation between a biallelic marker allele and a phenotype and/or between a biallelic marker haplotype and a phenotype.
    Type: Application
    Filed: August 15, 2005
    Publication date: February 23, 2006
    Applicant: Serono Genetics Institute S.A.
    Inventors: Marta Blumenfeld, Ilya Chumakov, Lydie Bougueleret, Annick Cohen-Akenine
  • Schizophrenia associated genes, proteins and biallelic markers
    Publication number: 20050260667
    Abstract: The invention concerns the human sbg1, g34665, sbg2, g35017 and g35018 genes, polynucleotides, polypeptides biallelic markers, and human chromosome 13q31-q33 biallelic markers. The invention also concerns the association established between schizophrenia and bipolar disorder and the biallelic markers and the sbg1, g34665, sbg2, g35017 and g35018 genes and nucleotide sequences. The invention provides means to identify compounds useful in the treatment of schizophrenia, bipolar disorder and related diseases, means to determine the predisposition of individuals to said disease as well as means for the disease diagnosis and prognosis.
    Type: Application
    Filed: June 6, 2005
    Publication date: November 24, 2005
    Applicant: Genset S.A.
    Inventors: Daniel Cohen, Marta Blumenfeld, Ilya Chumakov, Lydie Bougueleret, Bernard Bihain, Laurent Essioux
  • Assays for the detection of human defensin polypeptide (Def-X)
    Patent number: 6960441
    Abstract: The present invention relates to a novel human polypeptide defensin Def-X, genomic DNA and cDNA encoding Def-X, vectors containing Def-X encoding polynucleotides, and cells transformed with these vectors. The invention also provides for the use of Def-X polypeptides as an antibiotic, a cytotoxic, repair, and endocrine regulatory agent, and as pesticide. Def-X can also be used as agent, a cosmetic or pharmaceutical compositions for the treatment of microbial infections, in particular bacterial, fungal, and viral infections, parasitic infections, cancer, inflammation, and immune deficiencies. The invention provides diagnostic methods and kits for the determination of a microbial or parasitic infection and/or inflammation; also provided are methods of screening for predisposition to immune deficiencies or cancer.
    Type: Grant
    Filed: December 10, 2001
    Date of Patent: November 1, 2005
    Assignee: Serono Genetics Institute, S.A.
    Inventors: Lydie Bougueleret, Ilya Chumakov
  • High throughput DNA sequencing vector
    Patent number: 6955902
    Abstract: High throughput DNA sequencing vectors for generating nested deletions using enzymatic techniques and/or transposition-based techniques are disclosed. Methods of constructing contigs of long DNA sequences and methods of generating nested deletions are also disclosed. A truncated lacZ derivative useful in measuring the copy number of the lacZ derivative in a host cell is also disclosed.
    Type: Grant
    Filed: May 4, 2001
    Date of Patent: October 18, 2005
    Assignee: Serono Genetics Institute, Inc.
    Inventors: Ilya Chumakov, Hiroaki Tanaka
  • Genomic sequence of the 5-Lipoxygenase-activating protein (FLAP), polymorphic markers thereof and methods for detection of asthma
    Publication number: 20050196752
    Abstract: The invention concerns the genomic sequence of the FLAP gene. The invention also concerns biallelic markers of a FLAP gene and the association established between these markers and diseases involving the leukotriene pathway such as asthma. The invention provides means to determine the predisposition of individuals to diseases involving the leukotriene pathway as well as means for the diagnosis of such diseases and for the prognosis/detection of an eventual treatment response to agents acting on the leukotriene pathway.
    Type: Application
    Filed: February 5, 2003
    Publication date: September 8, 2005
    Applicant: Genset S.A.
    Inventors: Marta Blumenfeld, Ilya Chumakov, Lydie Bougueleret
  • PG-3 and biallelic markers thereof
    Publication number: 20050158779
    Abstract: The invention concerns the genomic sequence and cDNA sequences of the PG-3 gene. The invention also concerns biallelic markers of the PG-3 gene. The invention also concerns polypeptides encoded by the PG-3 gene. The invention also deals with antibodies directed specifically against such polypeptides that are useful as diagnostic reagents.
    Type: Application
    Filed: January 4, 2005
    Publication date: July 21, 2005
    Applicant: Genset S.A.
    Inventors: Caroline Barry, Ilya Chumakov
  • Biallelic markers derived from genomic regions carrying genes involved in arachidonic acid metabolism
    Publication number: 20050014190
    Abstract: The invention provides polynucleotides including biallelic markers derived from genes involved in arachidonic acid metabolism and from genomic regions flanking those genes. Primers hybridizing to regions flanking these biallelic markers are also provided. This invention also provides polynucleotides and methods suitable for genotyping a nucleic acid containing sample for one or more biallelic markers of the invention. Further, the invention provides methods to detect a statistical correlation between a biallelic marker allele and a phenotype and/or between a biallelic marker haplotype and a phenotype.
    Type: Application
    Filed: August 25, 2004
    Publication date: January 20, 2005
    Inventors: Marta Blumenfeld, Lydie Bougueleret, Ilya Chumakov, Annick Cohen
  • Nucleic acids encoding human TBC-1 protein and polymorphic markers thereof
    Patent number: 6825004
    Abstract: The invention concerns genomic and cDNA sequences of the human TBC-1 Gene. The invention also concerns polypeptides encoded by the TBC-1 gene. The invention also deals with antibodies directed specifically against such polypeptides that are useful as diagnostic reagents. The invention further encompasses biallelic markers of the TBC-1 gene useful in genetic analysis.
    Type: Grant
    Filed: June 25, 2001
    Date of Patent: November 30, 2004
    Assignee: Genset S.A.
    Inventors: Marta Blumenfeld, Lydie Bougueleret, Ilya Chumakov
  • Polymorphic markers of prostate carcinoma tumor antigen -1(PCTA-1)
    Publication number: 20040235037
    Abstract: The invention concerns the geNo.mic sequence and cDNA sequences of the PCTA-1 gene. The invention also concerns biallelic markers of the PCTA-1 gene and the association established between these markers and prostate cancer. The invention provides means to determine the predisposition of individuals to prostate cancer as well as means for the diagNo.sis of prostate cancer and for the progNo.sis/detection of an eventual treatment response to agents acting against prostate cancer.
    Type: Application
    Filed: May 27, 2004
    Publication date: November 25, 2004
    Inventors: Marta Blumenfeld, Lydie Bougueleret, Ilya Chumakov
  • Use of PP2A phosphatase modulators in the treatment of mental disorders
    Publication number: 20040203128
    Abstract: The invention relates to the use of PP2A/B&ggr; and to the use of a PP2A phosphatase comprising the PP2A/B&ggr; subunit for screening for modulators thereof. The use of these modulators for treating mental disorders such as bipolar disorder, schizophrenia and depression, and drugs comprising these modulators are further disclosed. The present invention further provides novel PP2A/B&ggr; subunits generated by alternative splicing events. The invention also discloses biallelic markers located in the gene encoding PP2A/B&ggr; and their use for diagnosing mental disorders.
    Type: Application
    Filed: December 23, 2003
    Publication date: October 14, 2004
    Applicant: Genset S.A.
    Inventors: Daniel Cohen, Ilya Chumakov, Marta Blumenfeld, Sanober Shaikh, Marta Palicio-Barron, Hadi Abderrahim, Pascale Grel, Laurent Cavarec
  • Biallelic markers derived from genomic regions carrying genes involved in arachidonic acid metabolism
    Patent number: 6794143
    Abstract: The invention provides polynucleotides including biallelic markers derived from genes involved in arachidonic acid metabolism and from genomic regions flanking those genes. Primers hybridizing to regions flanking these biallelic markers are also provided. This invention also provides polynucleotides and methods suitable for genotyping a nucleic acid containing sample for one or more biallelic markers of the invention. Further, the invention provides methods to detect a statistical correlation between a biallelic marker allele and a phenotype and/or between a biallelic marker haplotype and a phenotype.
    Type: Grant
    Filed: June 10, 2002
    Date of Patent: September 21, 2004
    Assignee: Genset S.A.
    Inventors: Marta Blumenfeld, Lydie Bougueleret, Ilya Chumakov, Annick Cohen
  • PG-3 and biallelic markers thereof
    Publication number: 20040163137
    Abstract: The invention concerns the genomic sequence and cDNA sequences of the PG-3 gene. The invention also concerns biallelic markers of the PG-3 gene. The invention also concerns polypeptides encoded by the PG-3 gene. The invention also deals with antibodies directed specifically against such polypeptides that are useful as diagnostic reagents.
    Type: Application
    Filed: March 15, 2004
    Publication date: August 19, 2004
    Inventors: Caroline Barry, Ilya Chumakov
  • Polymorphic markers of prostate carcinoma tumor antigen-1(PCTA-1)
    Patent number: 6759192
    Abstract: The invention concerns the geNo.mic sequence and cDNA sequences of the PCTA-1 gene. The invention also concerns biallelic markers of the PCTA-1 gene and the association established between these markers and prostate cancer. The invention provides means to determine the predisposition of individuals to prostate cancer as well as means for the diagNo.sis of prostate cancer and for the progNo.sis/detection of an eventual treatment response to agents acting against prostate cancer.
    Type: Grant
    Filed: June 4, 1999
    Date of Patent: July 6, 2004
    Assignee: Genset S.A.
    Inventors: Marta Blumenfeld, Lydie Bougueleret, Ilya Chumakov